All opioids (narcotic drugs like morphine or hydrocodone) induce respiratory depression, which is invariably the cause of death in cases of overdose
In 2020, 273 people died each day in the US from an opioid overdose - more than the number from automobile accidents or gun violence
The US economic burden of this crisis is estimated to be greater than $78 billion annually
The Challenge of Abuse Deterrence
Many opioids with abuse-deterrent formulations have been approved by FDA in recent years
However, these products offer no safety benefit (still cause lethal respiratory depression in overdose)
Furthermore, while these products may limit intravenous or nasal abuse, they do not deter oral over-consumption - the most common form of abuse of prescription opioids
The Quivive Solution
Functional Antagonism
All opioids cause respiratory depression, which is mediated by the same receptor target responsible for analgesia (can't have one without the other)
This is why opioid antagonists like Narcan also eliminate the analgesic effects of opioids
A functional antagonist reduces undesired side-effects without impacting opioid analgesia
Doxapram is FDA-approved for opioid-induced respiratory depression w/out impacting analgesia
Fewer Opioid Side Effects
Laxatives are routinely prescribed for opioid-induced constipation, but the most dangerous side effect was left untreated – until Now
In addition to preventing deadly respiratory depression, Doxapram may counteract other undesirable opioid side effects
Patented Abuse Deterrence Technology
Psychiatrists use Doxapram to safely induce anxiety attacks, but high doses are needed for these effects
Hydrocodone is the most widely abused prescription opioid - especially among school age children
More than 90% of addicts started by abusing prescription opioids like hydrocodone
Closes the primary gateway to later opioid addiction
Downloads - Executive Summary and COMPANY Slide Deck